Recent Updates
Recently added Catalysts
OVID Positive Sentiment

Columbia University

Friday, September 22, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Ovid and Columbia University Irving Medical Center have initiated a strategic research collaboration aimed at developing genetic-based therapies for rare neurological conditions. This partnership will leverage Columbia's expertise in rare disease genetics and Ovid's clinical development capabilities. The collaboration is expected to enhance Ovid's drug development portfolio and benefit individuals with rare genetic neurological disorders.
Price reaction · baseline $3.515 (2023-09-22T16:09:00.000Z) · hit during market hours · 27 other OVID headline(s) in the window, move may be shared
day 0 close · peak
+3.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Collaboration aims to advance genetic-based therapies.
  • Potential to expand Ovid's drug development portfolio.
  • Focus on rare neurological conditions can significantly impact patients.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+622%
120-day peak, hindsight
Typical move
2.4%
average across 3 past catalysts
Cash runway
~33 mo
Minimal dilution risk

Full Press Release Details

In June 2020, Ovid and Columbia University Irving Medical Center (“Columbia”) began a strategic research collaboration to advance genetic-based therapies for a range of rare neurological conditions, complementary of Ovid’s pipeline. This collaboration provided Ovid with the potential to expand its future drug development portfolio and impact individuals living with rare genetic neurological conditions by working closely with the Precision Medicine Resource at the Irving Institute at Columbia. Under this research and translational development alliance, Columbia will align its expertise in rare disease genetics and deep clinical understanding of rare neurological diseases with Ovid’s discovery, translational, and clinical development expertise in neurodevelopmental disorders and rare epilepsies.
Read Ovid press release »

Frequently Asked Questions

What is the focus of the Ovid and Columbia collaboration?

The collaboration focuses on advancing genetic-based therapies for rare neurological conditions.

When did Ovid and Columbia University start their partnership?

The partnership began in June 2020.

How will the collaboration benefit patients?

It aims to impact individuals living with rare genetic neurological conditions.

What expertise does Columbia bring to the collaboration?

Columbia offers expertise in rare disease genetics and clinical understanding of neurological diseases.

ShareAdd on Google
Tags: OVID Viatris Investor Conferences Healthcare Ovid Columbia University neurological conditions genetic therapies rare diseases
Last updated: Sep 22, 2023

Biotech snapshot

Cash runway
$166M liquidity · $5M/mo burn
~33 mo
Minimal dilution risk

Catalyst track record

+622%
best trade around OVID's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for OVID.

See every catalyst's timing & PoA →